New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
07:31 EDTGERN, ARGS, THLD, MDCO, EGRX, ANAC, SGMO, INSY, DSCO, XLRNPiper Jaffray to hold a symposium
Catalyst Symposium to be held in Boston on July 8.
News For ANAC;ARGS;DSCO;EGRX;GERN;INSY;MDCO;XLRN;SGMO;THLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 15, 2015
17:18 EDTMDCOThe Medicines Co. confirms FDA Advisory Committee backs approval of cangrelor
Subscribe for More Information
15:37 EDTMDCOFDA panel votes in favor of approval for cangrelor
Subscribe for More Information
07:57 EDTMDCOThe FDA Cardiovascular & Renal Drugs Advisory Committee to hold a meeting
The Committee discusses The Medicines Company's New Drug Application (NDA) 204958 Cangrelor injection for proposed indication of reduction of thrombotic cardiovascular events at a meeting being held at FDA Silver Spring, Maryland offices on April 15 at 8 am. Webcast Link
07:01 EDTMDCOThe Medicines Co. stock trading halted today
Subscribe for More Information
April 14, 2015
14:47 EDTINSYInsys Therapeutics management to meet with Jefferies
Meetings to be held in Denver/San Francisco on April 16-17 hosted by Jefferies.
11:05 EDTEGRXEagle Pharmaceuticals price target raised to $65 from $51 at Cantor
Subscribe for More Information
08:11 EDTARGSArgos Therapeutics licenses Arcelis platform to Lummy HK
Subscribe for More Information
08:03 EDTEGRXTeva, Eagle announce NDA for bendamustine HCI accepted for filing
Subscribe for More Information
April 13, 2015
17:21 EDTARGSArgos Therapeutics enters license agreement with Lummy for Arcelis
Subscribe for More Information
13:25 EDTEGRXEagle Pharmaceuticals appoints Fibrocell CEO to board of directors
Subscribe for More Information
11:13 EDTMDCOFDA panel briefing docs look positive for Medicines Co., says Leerink
Subscribe for More Information
10:15 EDTMDCOHigh option volume stocks
Subscribe for More Information
April 10, 2015
07:09 EDTMDCOThe Medicines Co. outlook still upbeat after preannouncement, says RBC Capital
After The Medicines Co preannounced lower than expected Q1 revenue, RBC Capital remains upbeat on the company's outlook, citing what it sees as the success of the company's gram negative franchise, its progress on earlier stage, cardiovascular candidates, and approval of and revenue support from up to four products in the near-term. The firm says the shares are "fundamentally inexpensive," while the company has a number of upcoming catalysts. It trimmed its price target on the shares to $37 from $38 but keeps an Outperform rating on the stock.
06:46 EDTMDCOThe Medicines Co. selloff a buying opportunity, says Leerink
Leerink views the selloff in shares of The Medicines Co. after the company preannounced weaker than expected Q1 revenue as a buying opportunity. The firm expects upcoming pipeline catalysts to create value in 2015. It thinks more visibility into four new products with significant revenue potential will move the stock higher. Leerink believes the preannouncement, driven by hospital customers buying fewer products due to the potential for a generic Angiomax to become available, should not come as a surprise. It keeps an Outperform rating on The Medicines Co.
April 9, 2015
16:32 EDTMDCOThe Medicines Co. down 15% after weaker than expected Q1 guidance
Subscribe for More Information
16:16 EDTMDCOThe Medicines Co. to resume trading at 4:30 pm ET
Subscribe for More Information
16:03 EDTMDCOThe Medicines Co. reports preliminary Q1 revenue $125M-$130M, consensus $184.17M
Subscribe for More Information
16:01 EDTMDCOThe Medicines Co. trading halted, pending news
Subscribe for More Information
April 7, 2015
10:51 EDTEGRXEagle Pharmaceuticals announces new patent for low-sodium bendamustine
Eagle Pharmaceuticals announced that the United States Patent and Trademark Office has granted Patent No. 9,000,021 for the use of bendamustine for treating patients requiring restricted fluid and/or sodium intake. The patent issued today expires in March 2033. On February 13, 2015, Eagle submitted a New Drug Application to the FDA for bendamustine hydrochloride for administration in a 50mL admixture for the treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Eagle has requested Priority Review of the NDA; this product candidate has received Orphan Drug Designations for both CLL and indolent B-cell NHL, and therefore may be eligible for seven years of exclusivity upon approval.
April 6, 2015
07:04 EDTXLRNAcceleron names Francois Nader as chairman
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use